{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:18:47Z","timestamp":1792091927593,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","award":["R01AI068804"],"award-info":[{"award-number":["R01AI068804"]}],"id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["10-0065"],"award-info":[{"award-number":["10-0065"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI119446"],"award-info":[{"award-number":["R01AI119446"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001763","name":"Australia-China Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["1155223"],"award-info":[{"award-number":["1155223"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["115620"],"award-info":[{"award-number":["115620"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["115737"],"award-info":[{"award-number":["115737"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["ID 1044941"],"award-info":[{"award-number":["ID 1044941"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1044941"],"award-info":[{"award-number":["1044941"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1065736"],"award-info":[{"award-number":["1065736"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.cmi.2016.10.023","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T16:05:49Z","timestamp":1478016349000},"page":"533-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition"],"prefix":"10.1016","volume":"23","author":[{"given":"P.N.A.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.C.","family":"Lye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"V.G.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.S.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Leibovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Llewelyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Munoz-Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.Y.","family":"Peleg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rodr\u00edguez-Ba\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Thamlikitkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Thwaites","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Y.C.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Turnidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Utili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.R.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2016.10.023_bib1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/1469-0691.12195","article-title":"Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe","volume":"19","author":"Goto","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2016.10.023_bib2","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/imj.12536","article-title":"Infectious diseases consultations at an Australian tertiary hospital: a review of 11,511 inpatient consultations","volume":"44","author":"Bursle","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.cmi.2016.10.023_bib3","doi-asserted-by":"crossref","first-page":"O737","DOI":"10.1111\/1469-0691.12581","article-title":"What do infectious diseases physicians do? A 2-week snapshot of inpatient consultative activities across Australia, New Zealand and Singapore","volume":"20","author":"Ingram","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2016.10.023_bib4","first-page":"12","article-title":"The Delphi Technique: making sense of consensus","author":"Hsu","year":"2007","journal-title":"Pract Assess Res Eval"},{"key":"10.1016\/j.cmi.2016.10.023_bib5","first-page":"179","article-title":"A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study","volume":"15","author":"Dulhunty","year":"2013","journal-title":"Crit Care Resusc"},{"key":"10.1016\/j.cmi.2016.10.023_bib6","doi-asserted-by":"crossref","first-page":"M139","DOI":"10.1093\/geronj\/46.4.M139","article-title":"The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients","volume":"46","author":"Crooks","year":"1991","journal-title":"J\u00a0Gerontol"},{"key":"10.1016\/j.cmi.2016.10.023_bib7","article-title":"Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (CPMP\/EWP\/558\/95 rev 2)","author":"European Medicines Agency","year":"2011","journal-title":"EMA"},{"key":"10.1016\/j.cmi.2016.10.023_bib8","series-title":"Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry (UCM070981)","author":"Food and Drug Administration","year":"2015"},{"key":"10.1016\/j.cmi.2016.10.023_bib9","series-title":"CAMERA \u2013 Combination Antibiotic treatment for Methicillin Resistant Staphylococcus Aureus","author":"Davis","year":"2010"},{"key":"10.1016\/j.cmi.2016.10.023_bib10","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.41.5.1127","article-title":"Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study","volume":"41","author":"Leibovici","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2016.10.023_bib11","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1001\/archinte.163.17.2066","article-title":"Clinical identifiers of complicated Staphylococcus aureus bacteremia","volume":"163","author":"Fowler","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2016.10.023_bib12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/0003-4819-115-8-585","article-title":"Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy","volume":"115","author":"Chow","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2016.10.023_bib13","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1086\/314712","article-title":"Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients","volume":"179","author":"Fowler","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2016.10.023_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","article-title":"Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study","volume":"82","author":"Chang","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cmi.2016.10.023_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nm0696-625","article-title":"HIV viral load markers in clinical practice","volume":"2","author":"Saag","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2016.10.023_bib16","first-page":"13234","article-title":"New drug, antibiotic, and biological drug product regulations: accelerated approval","volume":"57","author":"Food and Drug Administration","year":"1992","journal-title":"Federal Register"},{"key":"10.1016\/j.cmi.2016.10.023_bib17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2016.10.023_bib18","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2016.10.023_bib19","doi-asserted-by":"crossref","first-page":"R645","DOI":"10.1186\/cc3821","article-title":"Mortality prediction using SAPS II: an update for French intensive care units","volume":"9","author":"Le Gall","year":"2005","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2016.10.023_bib20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/dmp.2010.40","article-title":"A modified sequential organ failure assessment score for critical care triage","volume":"4","author":"Grissom","year":"2010","journal-title":"Disaster Med Public Health Prep"},{"key":"10.1016\/j.cmi.2016.10.023_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2016.10.023_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/1745-6215-13-241","article-title":"Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial","volume":"13","author":"Thwaites","year":"2012","journal-title":"Trials"},{"key":"10.1016\/j.cmi.2016.10.023_bib23","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.10.023_bib24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2217\/fmb.14.35","article-title":"Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies","volume":"9","author":"Bettiol","year":"2014","journal-title":"Future Microbiol"},{"key":"10.1016\/j.cmi.2016.10.023_bib25","series-title":"Guidance for Industry Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment (UCM234907)","author":"Food and Drug Administration","year":"2014"},{"key":"10.1016\/j.cmi.2016.10.023_bib26","article-title":"Briefing document: Primary bacteremia due to Staphylococcus aureus (PBSA) and catheter-related blood stream infections (CRBSI)","author":"Food and Drug Administration","year":"2004","journal-title":"FDA"},{"key":"10.1016\/j.cmi.2016.10.023_bib27","series-title":"Workshop on development of new antibacterial medicines","author":"European Medicines Agency","year":"2013"},{"key":"10.1016\/j.cmi.2016.10.023_bib28","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/cid\/civ1002","article-title":"DOOR\/RADAR: A gateway into the unknown?","volume":"62","author":"Phillips","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.10.023_bib29","doi-asserted-by":"crossref","first-page":"e112224","DOI":"10.1371\/journal.pone.0112224","article-title":"Long term outcomes following hospital admission for sepsis using relative survival analysis: a prospective cohort study of 1,092 patients with 5 year follow up","volume":"9","author":"Davis","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2016.10.023_bib30","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/cid\/civ120","article-title":"Impact of infectious disease consultation on quality of care, mortality, and length of stay in Staphylococcus aureus bacteremia: results from a large multicenter cohort study","volume":"60","author":"Bai","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.10.023_bib31","doi-asserted-by":"crossref","first-page":"140216","DOI":"10.1098\/rsos.140216","article-title":"An investigation of the false discovery rate and the misinterpretation of p-values","volume":"1","author":"Colquhoun","year":"2014","journal-title":"R\u00a0Soc Open Sci"},{"key":"10.1016\/j.cmi.2016.10.023_bib32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.diagmicrobio.2006.06.015","article-title":"Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli","volume":"56","author":"Bin","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2016.10.023_bib33","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1086\/444456","article-title":"Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis","volume":"41","author":"Chierakul","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.10.023_bib34","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/jac\/dkq088","article-title":"Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC)","volume":"65","author":"Corona","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2016.10.023_bib35","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1378\/chest.13-3065","article-title":"A 16-year prospective study of community-onset bacteremic Acinetobacter pneumonia: low mortality with appropriate initial empirical antibiotic protocols","volume":"146","author":"Davis","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2016.10.023_bib36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.clinthera.2009.02.015","article-title":"Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study","volume":"31","author":"Deal","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2016.10.023_bib37","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","article-title":"Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"57","author":"Falcone","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.10.023_bib38","first-page":"293","article-title":"Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae","volume":"26","author":"Falcone","year":"2014","journal-title":"Ann Ig"},{"key":"10.1016\/j.cmi.2016.10.023_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1086\/648720","article-title":"Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials","volume":"50","author":"Gardiner","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.10.023_bib40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/jac\/dkt475","article-title":"Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial","volume":"69","author":"Giamarellos-Bourboulis","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"42","key":"10.1016\/j.cmi.2016.10.023_bib41","first-page":"75","article-title":"Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia","volume":"2014","author":"Jandourek","year":"1995","journal-title":"Hosp Pract"},{"key":"10.1016\/j.cmi.2016.10.023_bib42","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s15010-013-0428-9","article-title":"Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study","volume":"41","author":"Kaasch","year":"2013","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2016.10.023_bib43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/1745-6215-15-233","article-title":"Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial","volume":"15","author":"Kalimuddin","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.cmi.2016.10.023_bib44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2016.10.023_bib45","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s00134-014-3323-7","article-title":"Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting","volume":"40","author":"Montravers","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2016.10.023_bib46","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jinf.2012.08.007","article-title":"Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"65","author":"Park","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2016.10.023_bib47","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/jac\/dkn372","article-title":"Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates","volume":"62","author":"Rehm","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2016.10.023_bib48","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ijantimicag.2012.12.016","article-title":"Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials","volume":"41","author":"Rice","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2016.10.023_bib49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2796.2005.01598.x","article-title":"Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients","volume":"259","author":"Ruotsalainen","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.cmi.2016.10.023_bib50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","volume":"54","author":"Rodriguez-Bano","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.10.023_bib51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13063-014-0541-9","article-title":"Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial","volume":"16","author":"Harris","year":"2015","journal-title":"Trials"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16305122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16305122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:53:07Z","timestamp":1778799187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X16305122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1198743X16305122"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2016.10.023","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2016.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}